Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-2 immune complex
- Development stage
- Unknown
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intraperitoneal, Intravenous, Subcutaneous
01
Overview
IL-2 immune complex (IL-2c or IL-2cx) is an immunotherapeutic platform consisting of interleukin-2 (IL-2) cytokine non-covalently complexed with or genetically fused to an anti-IL-2 monoclonal antibody. By sterically or conformationally blocking specific receptor-binding sites on IL-2, these complexes redirect the cytokine's activity toward specific immune cell subsets while extending its short in vivo half-life. Depending on the clone of the anti-IL-2 antibody used, the complex can be biased toward either CD25-expressing regulatory T cells (Tregs) to promote immunosuppression and transplant tolerance, or CD122-expressing CD8+ T cells and natural killer (NK) cells to enhance antitumor immunity.
- Other names
- IL-2/anti-IL-2 antibody complexIL-2/anti-IL-2 complexIL-2/anti-IL-2 mAb complexIL-2cIL2cIL 2cIL-2cxIL2cxIL 2cxinterleukin-2 immune complexinterleukin2 immune complexinterleukin 2 immune complexinterleukin-2/anti-interleukin-2 monoclonal antibody complex
02
Targets
IL-2 (Interleukin 2)IL2RA (Interleukin-2 receptor alpha subunit)IL2RB (IL-2 receptor beta chain)IL2RG (Interleukin-2 receptor gamma subunit)
Beyond the preview
Go deeper on IL-2 immune complex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-2 immune complex.